Skip to main content
SpringerLink
Log in

Aminoglutethimide: Theoretical Considerations and Clinical Results in Advanced Prostate Cancer

  • Chapter
Endocrine Therapies in Breast and Prostate Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 39))

Abstract

In the United States, prostate cancer is the second most common cancer and the third most common cause of cancer death in men [1]. More than 90,000 new cases will be diagnosed in 1988; most will present with metastatic disease. The median survival for patients with newly diagnosed, metastatic prostate cancer is approximately three years. Since the pioneering work of Huggins and Hodges in the 1940s, which demonstrated the androgen-dependence of prostate cancer, suppression of testicular androgen secretion has been the mainstay of treatment for advanced disease. Approximately 70–80% of patients with advanced disease respond favorably to such initial therapy [2]. However, most responses to testicular androgen deprivation are incomplete and their duration is relatively short. The average time from initial androgen deprivation to further disease progression is one to two years [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Silverberg E, Lubera J (1986): Cancer statistics. Cancer 36:9–25.

    CAS  Google Scholar 

  2. Garnick MB, et al (1984): Leuprolide versus DES for metastatic prostate cancer. N Engl J Med 311:1281–1286.

    Article  Google Scholar 

  3. Resnick MI, Grayhack JT (1978): Treatment of Stage IV carcinoma of the prostate. Urol Clin North Am 2:141–161.

    Google Scholar 

  4. Klein LA (1979): Prostatic carcinoma. N Engl J Med 300:824–833.

    Article  PubMed  CAS  Google Scholar 

  5. Migeon CJ (1972): Adrenal androgens in man. Am J Med 53:606–626.

    Article  PubMed  CAS  Google Scholar 

  6. Scott WW, Meiron M, Walsh PC (1980): Hormonal therapy of prostatic cancer. Cancer 45: 1929–1936.

    PubMed  CAS  Google Scholar 

  7. Geller J, Albert JD, (1985): Adrenal androgen blockade in relapsed prostate cancer. Eur. J Cancer Clin Oncol 21:1127–1131.

    Article  PubMed  CAS  Google Scholar 

  8. Bardin WC, Peterson RE (1967): Studies of androgen production by the rat: testosterone and androstenedione content of blood. Endocrinology 80:38–44.

    Article  PubMed  CAS  Google Scholar 

  9. Walsh PC, Suteri PK (1975): Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate. J Urol 114:254–256.

    PubMed  CAS  Google Scholar 

  10. Sanford EJ, Paulson DF, Rohmer TJ, et al (1977). The effects of castration on adrenal testosterone secretion with prostatic carcinoma. J Urol 118:1019–1021.

    PubMed  CAS  Google Scholar 

  11. Sciarra F, Sarcini G, DiSilverio F, Gagliari V (1973): Plasma testosterone and androstenedione after orchiectomy in prostatic adenocarcinoma. J Endocrinol 2:101–109.

    CAS  Google Scholar 

  12. Harper ME, Pike A, Peeling WB, Griffiths K (1974): Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 60:117–125.

    Article  PubMed  CAS  Google Scholar 

  13. Geller J, Albert J, Loza D, et al (1978): DHT concentrations in human prostatic cancer tissue. J Clin Endocrinol Metab 46:440.

    Article  PubMed  CAS  Google Scholar 

  14. Geller J, Albert J, Nachtscheim A, Loza D (1984): Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 132:693–695.

    PubMed  CAS  Google Scholar 

  15. Tannock IF (1985): Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013–1021.

    PubMed  CAS  Google Scholar 

  16. Huggins C, Scott WW, (1945): Bilateral adrenalectomy in prostate cancer. Ann Surg 122: 1031–1041.

    Article  Google Scholar 

  17. Huggins C, Bergenstal DM (1952): Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res 12:134–140.

    PubMed  CAS  Google Scholar 

  18. Fergusson JD (1953): Total adrenalectomy for malignant disease of the prostate and breast. Proc R Soc Med 47:1007–1013.

    Google Scholar 

  19. Whitmore WF, Randall HT, Pearson OH, West CD (1954): Adrenalectomy in the treatment of prostatic cancer. Geriatrics 9:62–69.

    PubMed  Google Scholar 

  20. Morales PA, Brendler H, Hotchkiss RS (1955): The role of the adrenal cortex in prostatic cancer. J Urol 73:399–409.

    PubMed  CAS  Google Scholar 

  21. MacFarlane DA, Thomas LP, Harrison JH (1960): A survey of total adrenalectomy in cancer of the prostate. Am J Surg 99:562–572.

    Article  PubMed  CAS  Google Scholar 

  22. Bhanalaph T, Varkarakis MJ, Murphy GP (1974); Current status of bilateral adrenalectomy for advanced prostatic carcinoma. Ann Surg 179:17–23.

    Article  PubMed  CAS  Google Scholar 

  23. West CD, Hollander VP, Whitmore WF, et al (1952): The effect of bilateral adrenalectomy upon neoplastic disease in man. Cancer 5:1009–1018.

    Article  PubMed  CAS  Google Scholar 

  24. Mahoney EM, Harrison IH (1972): Bilateral adrenalectomy for palliative treatment of prostatic cancer. J Urol 108:936–938.

    PubMed  CAS  Google Scholar 

  25. Schoonees R, Schalch DS, Reynoso G, Murphy GP (1972): Bilateral adrenalectomy for advanced prostatic carcinoma. J Urol 108:123–125.

    PubMed  CAS  Google Scholar 

  26. Silverberg GD (1977): Hypophysectomy in the treatment of disseminated prostate carcinoma. Cancer 39:1727–1731.

    Article  PubMed  CAS  Google Scholar 

  27. Maddy JA, Winternitz WW, Narrell H (1971): Cryohypophysectomy in the management of advanced prostatic cancer. Cancer 28:322–328.

    Article  PubMed  CAS  Google Scholar 

  28. Tindall GT, Nettleton PS, Nixon DW (1979): Transsphenoidal hypophysectomy for disseminated carcinoma of the prostate gland. J Neurosurg 50:275–282.

    Article  PubMed  CAS  Google Scholar 

  29. Smith JA, Harmon JE, Roberts TS, Middleton RG (1984): Transphenoidal hypophysectomy in the management of carcinoma of the prostate. Cancer 53:2385–2387.

    Article  PubMed  Google Scholar 

  30. Ramirez LF, Levin AB (1984): Pain relief after hypophysectomy. Neurosurgery 14:499–504.

    Article  PubMed  CAS  Google Scholar 

  31. Stoliar B, Albert DJ (1974): SCH 13521 in the treatment of advanced carcinoma of the prostate. J Urol 111:803–6.

    PubMed  CAS  Google Scholar 

  32. Jacobs E, Schmidt JD, Weinstein SH, Flocks RH (1976): Comparison of flutamide (SCH-13521) and diethylstilbesterol in untreated advanced prostate cancer. Urology 8:231–233.

    Article  Google Scholar 

  33. Sogani PC, Whitmore WF (1979): Experience with flutamide in previously untreated patients with advanced prostatic cancer. J Urol 122:640–643.

    PubMed  CAS  Google Scholar 

  34. Gellar J, Albert J, Yen SC (1978): Treatment of advanced cancer of the prostate with megesterol acetate. Urology 12:537–541.

    Article  Google Scholar 

  35. Hayward WG (1953): The treatment of late relapse in prostatic carcinoma by cortisone. J Urol 69:152–156.

    PubMed  CAS  Google Scholar 

  36. MacAdams MR, White RH, Chipps BE (1986): Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 104:648–651.

    PubMed  CAS  Google Scholar 

  37. Cash R, Brough JA, Cohen MN, Satoh PS (1967): AG (Eliptin-CIBA) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol 27:1239–1248.

    Article  CAS  Google Scholar 

  38. Dexter RN, Fishman LM, Ney RL, Liddle GW (1967): Inhibition of adrenal corticosteroid synthesis by AG: studies of the mechanism of action. J Clin Endocrinol 27:473–480.

    Article  CAS  Google Scholar 

  39. Somojlik E, Santen RJ, Wells SA (1977): Adrenal suppression with AG. II. Differential effects of AG on plasma androstenedione and estrogen levels. J Clin Endocrinol Metab 45:480–487.

    Article  Google Scholar 

  40. Santen RJ, Cohn N, Misbin R, et al (1979): Acute effects of AG on testicular steroidogenesis in normal men. J Clin Endocrinol Metab 49:631–634.

    Article  PubMed  CAS  Google Scholar 

  41. Shessel FS, Block NL, Stover B, et al (1980): Endocrine manipulation of the Dunning prostatic adenocarcinoma. Invest Urol 17:529–533.

    PubMed  CAS  Google Scholar 

  42. Robinson MGR, Shearer RJ, Fergusson JD (1974): Adrenal suppression in the treatment of carcinoma of the prostate. Br J Urol 46:555–559.

    Article  PubMed  CAS  Google Scholar 

  43. Lipton J, Santen RJ (1974): Medical adrenalectomy using AG and dexamethasone in advanced breast cancer. Cancer 33:503.

    Article  PubMed  CAS  Google Scholar 

  44. Sanford EJ, Drago JR, Rohner TJ, et al (1976): Aminoglutethimide: medical adrenalectomy for advanced prostatic carcinoma. J Urol 115:170–174.

    PubMed  CAS  Google Scholar 

  45. Santen RJ, Lipton A, Kendall J (1974): Successful medical adrenalectomy with aminoglutethimide—role of altered drug metabolism. JAMA 230:1661–1665.

    Article  PubMed  CAS  Google Scholar 

  46. Rostom AY, Folkes A, Lord C, et al (1982): Aminoglutethimide therapy for advanced carcinoma of the prostate. Br J Urol 54:552–555.

    Article  PubMed  CAS  Google Scholar 

  47. Schmidt JD, et al (1980): Chemotherapy programs of the National Prostate Cancer Project (NPCP). Cancer 45:1937–1946.

    PubMed  CAS  Google Scholar 

  48. Loening SA, et al (1983). J Urol 129:1001–1005.

    PubMed  CAS  Google Scholar 

  49. Block M, Trump D, Rose DP, et al (1984): Evaluation of AG in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy. Cancer Treat Rep 68:719–722.

    PubMed  CAS  Google Scholar 

  50. Murray R, Pitt P (1985): Treatment of advanced prostate cancer, resistant to conventional therapy, with aminoglutethimide. Eur J Cancer Clin Oncol 21:153–158.

    Google Scholar 

  51. Ponder BAJ, Shearer RJ, Pocock RD, et al (1984): Response to AG and cortisone acetate in advanced prostatic cancer. Br J Cancer 50:757–763.

    Article  PubMed  CAS  Google Scholar 

  52. Drago JR, Santen RJ, Lipton A, et al (1984): Clinical effect of AG, medical adrenalectomy, in the treatment of 43 patients with advanced prostatic carcinoma. Cancer 53:1447–1450.

    Article  PubMed  CAS  Google Scholar 

  53. Samojlik E, Kirschner MA, Lippman AJ, (1985): Clinical response and changes in hormonal milieu in men treated with medical adrenalectomy for advanced prostate cancer. Proc Am Soc Clin Oncol 4:97.

    Google Scholar 

  54. Crawford ED, et al (1984): Aminoglutethimide in adenocarcinoma of the prostate. Proc Am Soc Clin Oncol 3:157.

    Google Scholar 

  55. Worgul TJ, Santen RJ, Samojlik E, et al (1983): Clinical and biochemical effect of AG in the treatment of advanced prostatic carcinoma. J Urol 129:51–55.

    PubMed  CAS  Google Scholar 

  56. Messeih AA, Lipton A, Santen RJ, et al (1985): AG-induced hematologic toxicity:world-wide experience. Cancer Treat Rep 69:1003–1004.

    PubMed  CAS  Google Scholar 

  57. Pont A, et al (1982): Ketoconazole blocks steroid synthesis. Ann Intern Med 97:370.

    PubMed  CAS  Google Scholar 

  58. Loose DS, et al (1983): Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 71:1495.

    Article  PubMed  CAS  Google Scholar 

  59. Trachtenberg J, Halpern N, Pont A (1983): Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 130:152–153.

    PubMed  CAS  Google Scholar 

  60. Trachtenberg J (1984): Ketoconazole therapy in advanced prostate cancer. J Urol 132:61.

    PubMed  CAS  Google Scholar 

  61. Tapazoglou E, Subramanian MG, Al-Sarraf M, et al (1986): High-dose ketoconazole therapy in patients with metastatic prostate cancer. Am J Clin Oncol 9:369–375.

    Article  PubMed  CAS  Google Scholar 

  62. Havlin K, Trump D, et al (1987): Ketoconazole in advanced prostate cancer refractory to initial hormonal therapy: a clinical and endocrinologic study. Proc Am Soc Clin Oncol 6:106.

    Google Scholar 

  63. Labrie F, Dupont A, Belanger A (1985): Complete androgen blockade for the treatment of prostate cancer. In De Vita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology-1985. Philadelphia, Lippincott, pp 193–217.

    Google Scholar 

Download references

Authors
  1. Kathleen A. Havlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald L. Trump
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

    C. Kent Osborne

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Kluwer Academic Publishers, Boston

About this chapter

Cite this chapter

Havlin, K.A., Trump, D.L. (1988). Aminoglutethimide: Theoretical Considerations and Clinical Results in Advanced Prostate Cancer. In: Osborne, C.K. (eds) Endocrine Therapies in Breast and Prostate Cancer. Cancer Treatment and Research, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1731-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1731-9_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8974-6

  • Online ISBN: 978-1-4613-1731-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation